SACRÉ, Anne et al. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. Acta Oncologica, [S. l.], v. 55, n. 3, p. 329–340, 2016. DOI: 10.3109/0284186X.2015.1099731. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/25233. Acesso em: 30 jul. 2024.